Jane Estell

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +6

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F. Seymour, Pierre Feugier et al. · Journal of Clinical Oncology · 2019 · 278 citations · Full text

Medicine, Immunology, Oncology +10

Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants

Judith Trotman, Marion Fournier, T. Lamy et al. · Journal of Clinical Oncology · 2011 · 219 citations · Full text

Medicine, Oncology, Radiology +16

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Emmanuel Bachy, Matthew J. Maurer, Thomas M. Habermann et al. · Blood · 2018 · 206 citations · Full text

Medicine, Hematology, Oncology +9

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

María‐Victoria Mateos, Pieter Sonneveld, Vânia Hungria et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 153 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14